Cardioxyl Pharmaceuticals, Inc.

Johns Hopkins University

John P Toscano

Frederick Arthur Brookfield

Vincent Jacob Kalish

Stephen Martin Courtney

Lisa Marie Frost

Andrew D Cohen

Daryl A Guthrie

John Reardon

Saghar Nourian

Art Sutton

Vinayak S Khodade

Carl Leslie North

Art D Sutton

Christopher M Pavlos

Preeya Kapur Boppana

Patrick H Ruane

The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.

Nitroxyl donors with improved therapeutic index

A hydropersulfide precursor compound having the formula (I): formula (I) as defined in the specification. A process for preparing the hydropersulfide precursor, and a method of using the precursor to generate hydropersulfide are also described.

Hydropersulfide precursors

Alkylamine-substituted perthiocarbamates capable of controllable release of hydropersulfides (RSSH) and carbonyl sulfide (COS) and their use in treating or preventing ischemia-reperfusion injury are described.

Alkylamine-substituted perthiocarbamates as dual precursors to hydropersulfide and carbonyl sulfide

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

The present disclosure provides nitroxyl donating pharmaceutical compositions comprising N-substituted hydroxylamine derivatives. The compositions are highly efficacious in treating cardiovascular diseases (e.g., heart failure), have a suitable toxicological profile, and are sufficiently stable for intravenous or oral administration.

Pharmaceutical compositions comprising nitroxyl donors

O-substituted hydroxamic acids with carbon-based leaving groups as HNO donors are disclosed. Pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions also are disclosed.

O-substituted hydroxamic acids

The disclosed subject matter provides N-hydroxylsulfonamide derivative compounds of formulae (I), (II) or (III) as drawn below, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure. 

N-hydroxylsulfonamide derivatives as nitroxyl donors

N-substituted hydroxamic acids with carbon-based leaving groups as efficient HNO donors are disclosed. Pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions also are disclosed.

Growing community of inventors

Glen Arm, MD, United States of America

John P Toscano